Koninklijke DSM
Market Cap
€21.2b
Last Updated
2020/07/05 20:47 UTC
Data Sources
Company Financials +
Executive Summary
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, rest of Europe, North America, Latin America, China, India, Japan, rest of Asia, and internationally.
Rewards
Risk Analysis
No risks detected for DSM from our risk checks.
Snowflake Analysis
Flawless balance sheet average dividend payer.
Similar Companies
Share Price & News
How has Koninklijke DSM's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DSM has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
2.5%
DSM
2.4%
NL Chemicals
1.8%
NL Market
1 Year Return
11.2%
DSM
-3.0%
NL Chemicals
-12.5%
NL Market
Return vs Industry: DSM exceeded the Dutch Chemicals industry which returned -3% over the past year.
Return vs Market: DSM exceeded the Dutch Market which returned -12.5% over the past year.
Shareholder returns
| DSM | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.5% | 2.4% | 1.8% |
| 30 Day | 5.8% | 3.5% | -0.6% |
| 90 Day | 16.4% | 20.4% | 15.4% |
| 1 Year | 13.6%11.2% | -1.0%-3.0% | -9.7%-12.5% |
| 3 Year | 112.4%98.2% | 46.0%23.1% | 9.3%-2.0% |
| 5 Year | 170.2%137.8% | 67.3%36.7% | 28.2%4.2% |
Price Volatility Vs. Market
How volatile is Koninklijke DSM's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Does Koninklijke DSM's (AMS:DSM) Statutory Profit Adequately Reflect Its Underlying Profit?2 months ago | Simply Wall St
Is Koninklijke DSM N.V.’s (AMS:DSM) 7.9% Return On Capital Employed Good News?2 months ago | Simply Wall St
At €109, Is Koninklijke DSM N.V. (AMS:DSM) Worth Looking At Closely?Valuation
Is Koninklijke DSM undervalued compared to its fair value and its price relative to the market?
30.2x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DSM (€124.9) is trading above our estimate of fair value (€75.63)
Significantly Below Fair Value: DSM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DSM is poor value based on its PE Ratio (30.2x) compared to the Chemicals industry average (29x).
PE vs Market: DSM is poor value based on its PE Ratio (30.2x) compared to the Dutch market (16.7x).
Price to Earnings Growth Ratio
PEG Ratio: DSM is poor value based on its PEG Ratio (2.7x)
Price to Book Ratio
PB vs Industry: DSM is overvalued based on its PB Ratio (2.8x) compared to the NL Chemicals industry average (2.1x).
Next Steps
Future Growth
How is Koninklijke DSM forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
11.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DSM's forecast earnings growth (11.3% per year) is above the savings rate (0.4%).
Earnings vs Market: DSM's earnings (11.3% per year) are forecast to grow slower than the Dutch market (20.4% per year).
High Growth Earnings: DSM's earnings are forecast to grow, but not significantly.
Revenue vs Market: DSM's revenue (5.2% per year) is forecast to grow slower than the Dutch market (7.1% per year).
High Growth Revenue: DSM's revenue (5.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DSM's Return on Equity is forecast to be low in 3 years time (11.2%).
Next Steps
Past Performance
How has Koninklijke DSM performed over the past 5 years?
25.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DSM has high quality earnings.
Growing Profit Margin: DSM's current net profit margins (8%) are lower than last year (10.2%).
Past Earnings Growth Analysis
Earnings Trend: DSM's earnings have grown significantly by 25.7% per year over the past 5 years.
Accelerating Growth: DSM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DSM had negative earnings growth (-22.6%) over the past year, making it difficult to compare to the Chemicals industry average (-22%).
Return on Equity
High ROE: DSM's Return on Equity (9.6%) is considered low.
Next Steps
Financial Health
How is Koninklijke DSM's financial position?
Financial Position Analysis
Short Term Liabilities: DSM's short term assets (€5.6B) exceed its short term liabilities (€2.7B).
Long Term Liabilities: DSM's short term assets (€5.6B) exceed its long term liabilities (€3.5B).
Debt to Equity History and Analysis
Debt Level: DSM's debt to equity ratio (35%) is considered satisfactory.
Reducing Debt: DSM's debt to equity ratio has reduced from 60.5% to 35% over the past 5 years.
Debt Coverage: DSM's debt is well covered by operating cash flow (54.8%).
Interest Coverage: DSM's interest payments on its debt are well covered by EBIT (12.4x coverage).
Balance Sheet
Next Steps
Dividend
What is Koninklijke DSM current dividend yield, its reliability and sustainability?
1.92%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DSM's dividend (1.92%) isn’t notable compared to the bottom 25% of dividend payers in the Dutch market (2.24%).
High Dividend: DSM's dividend (1.92%) is low compared to the top 25% of dividend payers in the Dutch market (6.36%).
Stability and Growth of Payments
Stable Dividend: DSM's dividends per share have been stable in the past 10 years.
Growing Dividend: DSM's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (58%), DSM's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: DSM's dividends in 3 years are forecast to be well covered by earnings (46.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Dimitri de Vreeze (53yo)
0.42
Tenure
€2,175,000
Compensation
Mr. Dimitri de Vreeze serves as President of DSM Resins at DSM-AGI Corporation. Mr. de Vreeze has been a Member of Management Board at Koninklijke DSM N.V., (also known as Royal DSM N.V.) since September 1 ...
CEO Compensation Analysis
Compensation vs Market: Dimitri's total compensation ($USD2.45M) is below average for companies of similar size in the Dutch market ($USD4.90M).
Compensation vs Earnings: Dimitri's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-CEO & Member of the Managing Board | 0.42yr | €2.18m | 0.062% €13.1m | |
| Co-CEO & Member of the Managing Board | 0.42yr | €2.18m | 0.061% €13.0m | |
| EVP-Materials | 0.33yr | no data | no data | |
| Chief Innovation Officer & Member of Executive Committee | 0.92yr | no data | no data | |
| Senior VP of Corporate Control & Accounting and Group Controller | 7.92yrs | no data | no data | |
| Chief Technology Officer | 3.25yrs | no data | no data | |
| Vice President of Investor Relations | 8yrs | no data | no data | |
| Director of Legal Affairs and General Counsel | 8.25yrs | no data | no data | |
| Executive VP of Group People & Organisation | 2.5yrs | no data | no data | |
| Head of Energie Beheer Nederland | no data | no data | no data |
2.5yrs
Average Tenure
55yo
Average Age
Experienced Management: DSM's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Honorary Chairman | 0.33yr | €3.35m | 0.15% €31.8m | |
| Independent Chairman of Supervisory Board | 9.25yrs | €123.13k | no data | |
| Independent Member of Supervisory Board | 3.17yrs | €97.00k | 0.00062% €131.5k | |
| Deputy Chairwoman of Supervisory Board | no data | €95.21k | 0.00090% €190.8k | |
| Member of External Sustainability Advisory Board | no data | no data | no data | |
| Member of External Sustainability Advisory Board | no data | no data | no data | |
| Independent Member of Supervisory Board | 8.17yrs | €110.29k | no data | |
| Independent Member of Supervisory Board | 4.25yrs | €109.13k | no data | |
| Member of External Sustainability Advisory Board | no data | no data | no data | |
| Member of Sustainability Advisory Board | 4.42yrs | no data | no data |
4.3yrs
Average Tenure
65yo
Average Age
Experienced Board: DSM's board of directors are considered experienced (4.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Koninklijke DSM N.V.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Koninklijke DSM N.V.
- Ticker: DSM
- Exchange: ENXTAM
- Founded: 1902
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: €21.205b
- Shares outstanding: 169.77m
- Website: https://www.dsm.com
Number of Employees
Location
- Koninklijke DSM N.V.
- Het Overloon 1
- Heerlen
- Limburg
- 6411 TE
- Netherlands
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DSM | ENXTAM (Euronext Amsterdam) | Yes | Ordinary Shares | NL | EUR | Jan 1992 |
| DSM2 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| DSM | SWX (SIX Swiss Exchange) | Yes | Ordinary Shares | CH | CHF | Jan 1992 |
| KDSK.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| 0NPP | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| DSMA | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jan 1992 |
| RDSM | WBAG (Wiener Boerse AG) | Yes | Ordinary Shares | AT | EUR | Jan 1992 |
| DSM N | BMV (Bolsa Mexicana de Valores) | Yes | Ordinary Shares | MX | MXN | Jan 1992 |
| DSM2 | ETLX (Eurotlx) | Yes | Ordinary Shares | IT | EUR | Jan 1992 |
| RDSM.Y | OTCPK (Pink Sheets LLC) | SPON ADR | US | USD | Sep 1995 |
Biography
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, rest of Europe, North America, Latin America, China, India, Japan, rest of Asia, and internationally. It operates through Nutrition, Materials, and Innovation Center segments. The Nutrition segment offers animal nutrition and health products, including vitamins, enzymes, eubiotics, carotenoids, lipids, and minerals; human nutrition and health products comprising carotenoids, digestive enzymes, nutritional lipids, nutraceuticals, probiotic and prebiotics, and vitamins; and skin and sun care, hair care, and aroma ingredients. It also provides vitamin and lipid active pharmaceutical ingredients; omega-3 fatty acids; specialty enzymes, cultures, probiotics, bio-preservation, sugar reduction, and savory taste solutions; and specialty hydrocolloid solutions. The Materials segment provides thermoplastics used in automotive, electrical and electronics, building and construction, medical, food packaging, and consumer goods; coating resins and functional materials; Dyneema, a fiber solution for use in aviation, personal protection, marine, fishing, heavy lifting, and sports and lifestyle industries; and additives. The Innovation Center segment offers biomedical materials, and medical device and material manufacturing technologies in the areas of cardiovascular, dental, diabetes management, gynecology, neurology, ophthalmology, orthopedic, plastic and reconstructive surgery, soft tissue, and wound management. It also provides anti-reflective (AR) coatings for solar glass, retrofit AR and anti-soiling coatings, and conductive and PV backsheets; and yeast and enzymes for the conversion of starch, corn fiber, and biomass. The company has a partnership with Strait Access Technologies to develop trans-catheter replacement heart valves with polymeric leaflets. Koninklijke DSM N.V. was founded in 1902 and is headquartered in Heerlen, the Netherlands.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/05 20:47 |
| End of Day Share Price | 2020/07/03 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.